BASELINE CHARACTERISTICS AND TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM RA-BE-REAL PROSPECTIVE OBSERVATIONAL STUDY

被引：0
|
作者：
Balsa, A. [1 ]
Favalli, E. G. [2 ]
Ikeda, K. [3 ]
van de Laar, M. [4 ]
Schulze-Koops, H. [5 ]
Haladyj, E. [6 ]
Fakhouri, W. [6 ]
Ogwu, S. [6 ]
Laedermann, C. [6 ]
Finckh., A. [7 ]
机构：
[1] Hosp Univ La Paz, Inst Hlth Res IdiPAZ, Madrid, Spain
[2] Univ Studi Milano, ASST Gaetano Pini CTO, Milan, Italy
[3] Dokkyo Med Univ, Mibu, Japan
[4] Univ Twente, Enschede, Netherlands
[5] Ludwig Maximillians Univ Munich, Munich, Germany
[6] Eli Lilly & Co Ltd, Indianapolis, IN USA
[7] Univ Hosp Geneva, Geneva, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2024年 / 83卷
关键词：
D O I：
10.1136/annrheumdis-2024-eular.577
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0565
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Healthcare Resource Use by European Patients Enrolled in RA-BE-REAL: 12 Month Data From a Multinational, Prospective, Observational Study of Patients With Rheumatoid Arthritis
    Alten, R.
    Burmester, G.
    Matucci-Cerinic, M.
    Ostor, A.
    Zaremba-Pechmann, L.
    Treuer, T.
    Ng, K. J.
    Gerwien, J.
    Gibson, K.
    Fautrel, B.
    VALUE IN HEALTH, 2022, 25 (12) : S461 - S461
  • [2] A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB,TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) - STUDY DESIGN AND BASELINE CHARACTERISTICS
    Alten, R.
    Burmester, G. R.
    Matucci-Cerinic, M.
    Salmon, J. H.
    Lopez-Romero, P.
    Fakhouri, W.
    De La Torre, I.
    Gentzel-Jorczyk, A.
    Holzkaemper, T.
    Fautrel, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1157 - 1157
  • [3] Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study
    Taylor, Peter C.
    Fakhouri, Walid
    Ogwu, Samuel
    Haladyj, Ewa
    de la Torre, Inmaculada
    Fautrel, Bruno
    Alten, Rieke
    Nash, Peter
    Feist, Eugen
    RHEUMATOLOGY AND THERAPY, 2025, 12 (01) : 109 - 122
  • [4] INTERIM UPDATE ON BASELINE CHARACTERISTICS AND EFFECTIVENESS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB (FILOSOPHY)
    Caporali, R.
    Avouac, J.
    Bevers, K.
    Burmester, G. R.
    Debray, T.
    De Leonardis, F.
    Harris, K.
    Betteridge, N.
    Romero-Yuste, S.
    Verschueren, P.
    Zignani, M.
    Galloway, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 491 - 491
  • [5] Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
    Alten, Rieke
    Burmester, Gerd R.
    Matucci-Cerinic, Marco
    Salmon, Jean-Hugues
    Ostor, Andrew
    Ng, Khai Jing
    Gerwien, Jens
    Zaremba-Pechmann, Liliana
    Brnabic, Alan J. M.
    Fautrel, Bruno
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1575 - 1595
  • [6] Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
    Rieke Alten
    Gerd R. Burmester
    Marco Matucci-Cerinic
    Jean-Hugues Salmon
    Andrew Östör
    Khai Jing Ng
    Jens Gerwien
    Liliana Zaremba-Pechmann
    Alan J. M. Brnabic
    Bruno Fautrel
    Rheumatology and Therapy, 2023, 10 : 1575 - 1595
  • [7] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Alten, Rieke
    Burmester, Gerd R.
    Matucci-Cerinic, Marco
    Salmon, Jean-Hugues
    Lopez-Romero, Pedro
    Fakhouri, Walid
    de la Torre, Inmaculada
    Zaremba-Pechmann, Liliana
    Holzkaemper, Thorsten
    Fautrel, Bruno
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 73 - 93
  • [8] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Rieke Alten
    Gerd R. Burmester
    Marco Matucci-Cerinic
    Jean-Hugues Salmon
    Pedro Lopez-Romero
    Walid Fakhouri
    Inmaculada de la Torre
    Liliana Zaremba-Pechmann
    Thorsten Holzkämper
    Bruno Fautrel
    Rheumatology and Therapy, 2023, 10 : 73 - 93
  • [9] BASELINE CHARACTERISTICS OF AND EARLY OUTCOMES IN THE FIRST 200 PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH FILGOTINIB IN A PROSPECTIVE OBSERVATIONAL STUDY
    Galloway, James
    Bevers, Karen
    Verschueren, Patrick
    Caporali, Roberto
    Romero Yuste, Susana
    Avouac, Jerome
    Gvozdenovic, Emilia
    Harris, Kristina
    Zignani, Monia
    Burmester, Gerd
    RHEUMATOLOGY, 2023, 62
  • [10] RADIUS: Interim findings from a prospective, multicenter, observational, outcomes study in rheumatoid arthritis (RA) patients.
    Cush, JJ
    Lautzenheiser, RL
    Markenson, JA
    Spencer-Green, G
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S528 - S529
12345